Drug intelligence / Profile preview

TPST-3003

Development stage: Unknown
Lead developer: Tempest Therapeutics
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

**TPST-3003** is a discovery-stage investigational asset being pursued by Tempest Therapeutics for preclinical development. It is described as a CD19/BCMA parallel structured dual-CAR T cell therapy designed to target BCMA and CD19, potentially for oncology indications such as multiple myeloma or other B-cell malignancies. As a cell therapy modality, it aims to modulate BCMA and CD19 to enable targeted immune-mediated tumor cell killing. Limited public details are available on its specific mechanism, clinical status, or developers beyond Tempest's acquisition context from Factor Bioscience, with no reported clinical trials or efficacy data as of late 2025.[8][11]

Targets

BCMA (B-cell maturation antigen)CD19 (B lymphocyte antigen CD19)

Beyond the preview

Go deeper on TPST-3003.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TPST-3003.

Explore the full profile